RedTalks #3 Saison 3: Understanding the role of oncogenic drivers in T-cell lymphoma
CALYM Institute launches its RedTalks, a Series of scientific Webinars
Date : Thursday, February 2, 2023 – 6:00 PM (CET)
- Pr. Teresa Palomero, Professor of Pathology and Cell Biology at the Institute for Cancer Genetics-Columbia University
- Pr. Laurence de Leval, Head of the Clinical Pathology Service at the University Institute of Pathology (CHUV, Lausanne Switzerland)
- Pr. Philippe Gaulard, Physician of Pathological Anatomy and Cytology at Hôpital Henri Mondor (AP-HP, Creteil, France)
We are delighted to welcome Pr. Teresa Palomero, Professor of Pathology and Cell Biology at the Institute for Cancer Genetics-Columbia University.
Pr. Palomero’s studies the genetics and mechanisms of transformation in Peripheral T-cell Lymphoma (PTCL), a heterogenous group of mature T-cell malignancies. Her group developed a cutting-edge research program implementing the integrative use of whole exome sequencing, gene expression profiling and single cell sequencing to identify novel drivers of transformation and tumor evolution in PTCL. Her current research focuses on the elucidation of oncogenic mechanisms driven by genetic alterations, the development of genetically manipulated mouse models of T-cell lymphoma and the therapeutic targeting of key oncogenic pathways responsible for T-cell transformation.
During her postdoctoral training she participated in pioneer work in the development of the ChIP-on-chip technique in collaboration with Dr. Rick Young and applied this method to the characterization of the transcriptional regulatory networks downstream of the TAL1 oncogene in T-cell acute lymphoblastic leukemia.
After joining the faculty at Columbia University Pr. Palomero used gene expression profiling, ChIP-on-chip and ChIP-seq analysis for the identification of NOTCH1 direct target genes responsible for the transformation of T-cell progenitors and identified mutations in PTEN as responsible for resistance to gamma secretase inhibitor therapy in T-ALL and RUNX1 as a novel tumor suppressor in T-ALL. She has been using next generation sequencing analysis to identify novel mutations associated with T cell malignancies including those in the PHF6 gene, the NT5C2 mutations associated with chemotherapy resistance, the FYN and RHOA G17V mutations in Peripheral T-cell Lymphomas (PTCLs) and CARD11 and PKG1 in Cutaneous T-cell Lymphomas (CTCL).
During this RedTalk, Pr. Palomero will review the elucidation of the mutational landscape in angioimmunoblastic T-cell lymphoma and the role of specific recurrent alterations in T-cell development and malignant transformation.
Last but not least, we are also pleased to welcome great moderators: Pr. Laurence de Leval, Head of the Clinical Pathology Service at the University Institute of Pathology (CHUV, Lausanne Switzerland) and Pr. Philippe Gaulard, Physician of Pathological Anatomy and Cytology at Hôpital Henri Mondor (AP-HP, Creteil, France).